Wellysis, a digital healthcare company spun off from Samsung, has announced the launch of remote cardiac monitoring service in the US in partnership with Artella Solutions (ARTELLA).

This collaboration builds on its FDA-cleared S-Patch electrocardiogram monitoring solution, now featuring the newly FDA-cleared S-Patch ExL device. The ExL model allows for extended testing periods of about 14 days on a single coin battery and received FDA clearance in early February. With this milestone, Wellysis can now expand its reach in the Extended Holter service and Mobile Cardiac Telemetry (MCT) service.

Wellysis is introducing its S-Patch ExL solution to US patients thorough a partnership with ARTELLA, headquartered in Houston, Texas. ARTELLA provides comprehensive remote cardiac monitoring solution across 10 states. By teaming up, Wellysis and ARTELLA aim to deliver an unparalleled end-to-end cardiac monitoring service, commencing in Texas.

The newly launched program includes bundling of Samsung smartphones and smartwatches, seamlessly integrating with the S-Patch ExL device.

Wellysis CEO Young Juhn expressed excitement about this milestone collaboration, stating, "We are thrilled to partner with ARTELLA for our remote cardiac monitoring service in the US, introducing this end-to-end solution using S-Patch to US patients. This collaboration signifies the beginning of an exciting journey, with plans to integrate AI algorithms soon."

Sepand Moshiri, Co-Founder and CEO of ARTELLA, commented, "This organic journey has led to a dynamic partnership with Wellysis, combining forces to redefine the future of patient care. Together, we are at the forefront of cardiac monitoring innovation, harnessing the power of artificial intelligence and virtual real-time monitoring."

The groundbreaking collaboration will be unveiled at the upcoming American College of Cardiology (ACC) meeting in April.

In addition to this launch, Wellysis is actively working on obtaining FDA clearance for its AI algorithms, further cementing its commitment to innovation and advancing patient care.